- •Preface to the Second Edition
- •Contents
- •List of Abbreviations
- •1: Epidemiology of AMD
- •Core Messages
- •1.1 Introduction
- •1.3 Frequency
- •1.3.1 Prevalence
- •1.3.2 Incidence
- •1.4 Natural Course
- •1.5 Genetic Factors
- •1.5.1 The Complement Pathway Genes
- •1.5.1.1 Complement Factor H (CFH)
- •1.5.1.3 Complement Component 3 (C3)
- •1.5.1.4 Complement Factor I (CFI)
- •1.5.2 The ARMS2 (10q26) Locus
- •1.5.3.1 Apolipoprotein E (APOE)
- •1.5.4 Candidate Gene Association Studies
- •1.6 Environmental Factors
- •1.6.1 Smoking
- •1.6.2 Antioxidants
- •1.6.3 Body Mass Index (BMI)
- •1.6.4 Hypertension
- •1.6.5 Cataract Surgery
- •1.7 Interaction Between Risk Determinants
- •1.7.1 Combined Effects of CFH Y402H and Other Genetic and/or Environmental Factors
- •1.7.2 Combined Effects of 10q26 SNPs and Other Genetic and/or Environmental Factors
- •1.7.4 Combined Effects of the APOE Gene and Other Genetic and/or Environmental Factors
- •References
- •2: Genetics
- •Core Messages
- •2.1 Introduction
- •2.2 Identifying Risk Factors of a Common Disease
- •2.3 Early Findings
- •2.4.1 Functional Implications
- •2.5.1 Functional Implications
- •2.7 Prospects of Genetics in AMD Therapy and Prevention
- •Summary for the Clinician
- •References
- •Core Messages
- •3.1 Introduction
- •3.2 Cause and Consequences of Ageing
- •3.3 Clinical Changes Associated with Retinal Ageing
- •3.4 Ageing of the Neural Retina
- •3.5 Ageing of the RPE
- •3.5.1 Changes in RPE Cell Density
- •3.5.2 Subcellular Changes in the RPE
- •3.5.3 Accumulation of Lipofuscin
- •3.5.4 Melanosomes and Pigment Complexes
- •3.5.7 Antioxidant Capacity of the RPE
- •3.6 Ageing of Bruch’s Membrane
- •3.7 The Association Between Ageing and AMD
- •Summary for the Clinician
- •References
- •Core Messages
- •4.1 Introduction
- •4.2 The Complement System
- •4.3 Evidence for Involvement of the Complement System in AMD Pathogenesis
- •4.4.2 Complement Gene Variants and AMD Subtypes
- •4.4.3 Complement Gene Variants and Progression of AMD
- •4.4.5 Variations of Complement Genes and Response to Treatment: Pharmacogenetics
- •4.5 Emerging Pharmacological Intervention Targeting Complement Dysregulation
- •Conclusions
- •Summary for the Clinician
- •References
- •5: Histopathology
- •Core Messages
- •5.1 Retinal Pigment Epithelium
- •5.1.1 Structure and Function of the Retinal Pigment Epithelium
- •5.1.3 Deposits in the RPE
- •5.2 Bruch’s Membrane
- •5.2.1 Structure of Bruch’s Membrane
- •5.2.3 Deposits in Bruch’s Membrane, Drusen
- •5.3 Choroidal Neovascularization
- •5.4 Detachment of the Retinal Pigment Epithelium
- •5.5 Geographic Atrophy of the RPE
- •Summary for the Clinician
- •References
- •6: Early AMD
- •Core Messages
- •6.1 Introduction
- •6.2 Drusen
- •6.2.3 Fluorescence Angiography and Optical Coherence Tomography
- •6.3 Focal Hypopigmentation and Hyperpigmentation of the Retinal Pigment Epithelium
- •6.4 Abnormal Choroidal Perfusion
- •Summary for the Clinician
- •References
- •Core Messages
- •7.1 Introduction
- •7.2.1 Decreased Visual Acuity
- •7.2.2 Visual Distortion
- •7.2.3 Visual Field Defects
- •7.2.4 Miscellaneous Symptoms
- •7.3 Signs of Choroidal Neovascularization
- •7.3.1 Hemorrhage
- •7.3.2 Macular Edema and Subretinal Fluid
- •7.3.3 Retinal Pigment Epithelial Detachment
- •7.3.4 Miscellaneous Signs
- •7.4 Common Testing Modalities to Diagnose Choroidal Neovascularization
- •7.4.1 Fluorescein Angiography
- •7.4.2 Indocyanine Green Angiography
- •7.4.4 Optical Coherence Tomography
- •Summary for the Clinician
- •References
- •8: Geographic Atrophy
- •Core Messages
- •8.1 Introduction
- •8.3 Histology and Pathogenesis of Geographic Atrophy
- •8.5 Spectral Domain Optical Coherence Tomography in Geographic Atrophy
- •8.7 Risk Factors
- •8.7.1 Genetic Factors
- •8.7.2 Systemic Risk Factors
- •8.7.3 Ocular Risk Factors
- •8.8 Development of CNV in Eyes with GA
- •8.9 Visual Function in GA Patients
- •8.9.1 Measurement of Visual Acuity
- •8.9.2 Contrast Sensitivity
- •8.9.3 Reading Speed
- •8.9.4 Fundus Perimetry
- •8.10 Perspectives for Therapeutic Interventions
- •8.10.2 Complement Inhibition
- •8.10.3 Neuroprotection
- •8.10.4 Alleviation of Oxidative Stress
- •8.10.5 Serotonin-1A-Agonist
- •8.10.6 Perspective
- •Summary for the Clinician
- •References
- •9: Fundus Imaging of AMD
- •Core Messages
- •9.1 Introduction
- •9.2 Color Photography
- •9.3 Monochromatic Photography
- •9.5 Optical Coherence Tomography
- •9.5.2 Coherence Length
- •9.5.3 Time Domain Optical Coherence Tomography
- •9.5.4 Frequency Domain Optical Coherence Tomography
- •9.5.5 Increasing Depth of Imaging
- •9.5.6 General Optical Coherence Tomographic Imaging Characteristics of the Macular Region
- •9.6 Fundus Angiography
- •9.6.1 Fluorescein Dye Characteristics
- •9.6.2 Indocyanine Green Dye Characteristics
- •9.6.3 Cameras Used in Fluorescence Angiography
- •9.6.4 Patient Consent and Instruction
- •9.6.5 Fluorescein Injection
- •9.6.6 Fluorescein Technique
- •9.6.7 Indocyanine Green Technique
- •9.7 Fluorescein Angiographic Interpretation
- •9.7.1 Filling Sequence
- •9.7.2 The Macula
- •9.8 Deviations from Normal Angiographic Appearance
- •9.10.1 Drusen
- •9.12 Neovascular AMD
- •9.13 Retinal Pigment Epithelial Detachments
- •9.14 Retinal Vascular Contribution to the Exudative Process
- •9.15 Follow-up
- •9.15.1 Thermal Laser
- •9.15.2 Photodynamic Therapy
- •9.15.3 Anti-VEGF Therapy
- •Summary for the Clinician
- •References
- •10: Optical Coherence Tomography
- •10.1 Introduction
- •Core Messages
- •10.4 OCT in Geographic Atrophy
- •10.5 OCT in Exudative AMD
- •Summary for Clinician
- •References
- •11: Microperimetry
- •Core Messages
- •11.1 Introduction
- •11.2.1 From Manual to Automatic Microperimetry
- •11.2.2 Automatic Microperimetry
- •11.2.3 Microperimetry: The Examination
- •11.2.4 Microperimetry: Test Evaluation
- •11.2.5 Other Microperimeter
- •11.3 Microperimetry in AMD
- •11.3.1 Early AMD
- •11.3.2 Geographic Atrophy
- •11.3.3 Neovascular AMD
- •11.3.4 Neovascular AMD: Treatment
- •Summary for the Clinician
- •References
- •Core Messages
- •12.1 Introduction
- •12.2 Antioxidants and Zinc
- •12.3 Beta-Carotene
- •12.4 Macular Xanthophylls
- •12.6 Vitamin E
- •12.7 Vitamin C
- •12.8 Zinc
- •12.10 AREDS2
- •Summary for the Clinician
- •References
- •Core Messages
- •13.1 Introduction
- •13.2 Basic Principles
- •13.2.1 Clinical Background
- •13.2.2 Laser Photocoagulation
- •13.2.3 Photodynamic Therapy
- •13.3 Treatment Procedures
- •13.3.1 Laser Photocoagulation
- •13.3.2 Photodynamic Therapy
- •13.4 Study Results
- •13.4.1 Laser Photocoagulation
- •13.4.1.1 Extrafoveal CNV
- •13.4.1.2 Subfoveal CNV
- •13.4.1.3 Meta-analysis
- •13.4.2 Photodynamic Therapy
- •13.4.2.1 Predominantly Classic
- •13.4.2.2 Occult with No Classic Neovascularization
- •13.4.2.3 Minimally Classic
- •13.5 Safety and Adverse Events
- •13.5.1 Laser Photocoagulation
- •13.5.2 Photodynamic Therapy
- •13.6 Variations
- •13.6.1 Laser Photocoagulation: Different Wavelengths
- •13.6.2 Photodynamic Therapy
- •13.6.3 Combination Treatments
- •13.7 Present Guidelines
- •13.7.1 Laser Photocoagulation
- •13.7.2 Photodynamic Therapy
- •13.8 Perspectives
- •Summary for the Clinician
- •References
- •Core Messages
- •14.1 Introduction
- •14.2 Vascular Endothelial Growth Factor (VEGF)
- •14.3 Targets Within the VEGF Pathway
- •14.3.1 Sequestration of Released VEGF
- •14.3.2 Inhibition of VEGF and VEGF Receptor Synthesis by Small Interfering RNA (siRNA)
- •14.3.3 Inhibition of the Intracellular Signal Cascade
- •14.3.4 Natural VEGF Inhibitors
- •14.4 New Methods of Drug Delivery
- •14.5 Combined Strategies
- •Summary for the Clinician
- •References
- •Core Messages
- •15.1 Introduction
- •15.1.1 Anti-VEGF Therapies for NV-AMD
- •15.2.1 How Should Neovascular AMD be Diagnosed?
- •15.2.4.1 Results with Continuous Monthly Treatment
- •15.2.4.2 How Should Treatment be Started?
- •15.2.4.3 What Flexible Approaches Are Reported?
- •Fixed Quarterly Injection Studies
- •Flexible Dosing Regimens: Two Approaches
- •Flexible Dosing Regimens: ‘As Needed’ Approach
- •Flexible Dosing Regimens: ‘Treat-and-Extend’ Approach
- •Summary for the Clinician
- •References
- •Core Messages
- •16.1 Introduction
- •16.3 Current Limitation of Therapy in the Treatment of Exudative AMD
- •16.4 Rationale for Combination Therapy in the Treatment of Exudative AMD
- •16.5 Clinical Data Examining Combination Therapy for Exudative AMD
- •16.5.3 Triple Therapy for Exudative AMD
- •16.5.4 Combination Therapy with Radiation
- •Summary for the Clinician
- •References
- •Core Messages
- •17.1 Introduction
- •17.2 Current Treatment Options for Dry AMD
- •17.3 Targeting the Cause of AMD
- •17.4 Preclinical and Phase I Drugs in Development for Dry AMD
- •17.4.1 Clinical Trial Endpoints in Dry AMD
- •Trimetazidine
- •17.4.2.2 Neuroprotection
- •Ciliary Neurotrophic Factor (CNTF/NT-501)
- •AL-8309B (Tandospirone)
- •Brimonidine Tartrate Intravitreal Implant
- •17.4.2.3 Visual Cycle Modulators
- •Fenretinide
- •17.4.2.4 Other
- •17.4.3 Drugs to Prevent Injury from Oxidative Stress and Micronutrient Depletion
- •17.4.4.1 Complement Inhibition at C3
- •17.4.4.2 Complement Inhibition at C5
- •Eculizumab
- •17.4.4.3 Complement Inhibition of Factor D
- •FCFD4514S
- •Iluvien
- •Glatiramer Acetate (Copaxone)
- •17.5 Summary
- •Summary for the Clinician
- •References
- •18: Surgical Therapy
- •Core Messages
- •18.1 Maculoplasty
- •18.2 Macular Translocation
- •18.3 Single Cell Suspensions
- •18.5 Indications for Surgery
- •18.5.1 Non-responder
- •18.5.2 Pigment Epithelium Rupture
- •18.5.3 Massive Submacular Bleeding
- •18.5.5 Macula Dystrophies
- •Summary for the Clinician
- •References
- •19: Reading with AMD
- •Core Messages
- •19.1 Introduction
- •19.2 Physiological Principles
- •19.3 Reading with a Central Scotoma
- •19.3.1.2 The Reading Visual Field Related to the Fundus (Fig. 19.4b)
- •19.3.1.3 The Reading Visual Field Related to the Text (Fig. 19.4c)
- •19.3.1.4 Eccentric Fixation Related to the Globe (Fig. 19.5)
- •19.3.3 Examination of Fixation Behaviour
- •19.3.4 Motor Aspects
- •19.4 Methods to Examine Reading Ability
- •19.5 Rehabilitation Approaches to Improve Reading Ability
- •Summary for the Clinician
- •References
- •20: Low Vision Aids in AMD
- •Core Messages
- •20.2 Effects of Visual Impairment in AMD
- •20.5 Optical Magnifying Visual Aids for Distance
- •20.5.1 Aids for Watching Television
- •20.8 Electronic Reading Instruments
- •20.9 Additional Aids
- •20.10 Noteworthy Details for the Provision of Low Vision Aids
- •20.11 Basic Information on Prescription
- •Summary for the Clinician
- •References
- •Index
9 Fundus Imaging of AMD |
155 |
|
|
Fig. 9.9 This patient received 12 Gy of external beam radiation for choroidal neovascularization and had a cessation of exudation. During follow-up, the patient showed a resumption of
growth of the neovascularization that had growth characteristics similar to polypoidal choroidal vasculopathy. This condition is called radiation-associated choroidal neovasculopathy [31]
monotonically increasing amount of contrast between one area of staining and the surrounding choroid.
–The third main use of ICG angiography is to diagnose polypoidal choroidal vasculopathy (Figs. 9.7 and 9.8), which is a slow growing variant of CNV that has interconnecting vascular channels and aneurismal dilations at the outer border of the lesion. Some patients have developed a polypoidal-like change after having external beam radiation for CNV (Fig. 9.9).
It is common for both classic and occult neovascu-
larization to be present in one lesion. In that case, the areas of the relative types are used to characterize the lesion. If a lesion is 75% classic and 25% occult, the lesion is said to be predominantly classic. If the lesion is 25% classic and 75% the lesion could presumably be called predominantly occult, but this would bring up the difficultly of a lesion that is 25% classic and 75% blood. Since blood is not occult disease, this lesion could not be called predominantly occult. Therefore lesions with classic CNV occupying less than 50% of the total area are termed minimally classic lesions. This type of classification was useful during the era of photodynamic therapy for CNV, but is not particularly useful today.
9.13Retinal Pigment Epithelial Detachments
Although PEDs can occur in the context of non-neo- vascular AMD, most PEDs are related to CNV. The
relationship can occur in two main ways. First PEDs with a notch usually have occult CNV in the notch. Additional signs for the presence of occult CNV include blood or other exudative material in the PED, irregular elevation of the PED, subretinal blood or lipid adjacent to the PED, or the fluorescein angiographic findings of adjacent fibrovascular PED, late leakage of undetermined source, or irregular, heterogeneous filling of the PED. Choroidal neovascularization is difficult to image through a PED because of the melanin in the RPE as well as the rapid, intense build-up of fluorescence in the PED from fluorescein leakage. For this reason, studies of the treatment of CNV have often excluded patients with large PEDs. One strategy to characterize the extent of the CNV is to perform ICG angiography, which is neither limited by melanin pigment in the RPE or by leakage into the cavity of the PED. ICG angiography of notched PEDs commonly identifies the region involved with CNV. ICG angiography of large PEDs without a notch frequently shows an underlying plaque of CNV.
Using EDI-OCT the internal characteristics of fibrovascular PEDs were investigated. Many PEDs occurring in the context of AMD have evidence of CNV growing up the back surface of the RPE. Contraction of this fibrovascular material has been associated with the formation of RPE tears (Figs. 9.10 and 9.11).
In eyes with RPE tears, the detached monolayer of RPE scrolls toward the neovascularization, leaving a bared area of choroid exposed. It is theorized that
156 |
R.F. Spaide |
|
|
Fig. 9.10 This patient had choroidal neovascularization above the level of the retinal pigment epithelium (RPE, open arrowhead) and below the RPE (closed arrowhead) associated with pigment epithelial detachment (PED, the top of which is shown by the arrow, top) as visualized by enhanced depth imaging (EDI) optical coherence tomography (OCT). The middle
and bottom illustrations are successive sections taken inferiorly to the section illustrated at the top of the Figure. Note the increasing elevation of the PED. At the back surface of the PED is an accumulation of hyperreflective material contiguous with the layer of sub-RPE neovascularization (arrows in each section) (From Spaide [32])
this area is eventually repopulated by RPE cells, which often are completely devoid of pigment. During fluorescein angiography, the bared area is hyperfluorescent early, and depending on the amount of underlying CNV or by the seal of the scrolled RPE over any underlying CNV may show leakage. The
scrolled region of RPE is particularly dark, and blocks the underlying fluorescence. On occasion the scrolled area of RPE has been termed “doubly hypofluorescent.” This same scrolled RPE contains more lipofuscin in its vertical summation, and therefore appears doubly autofluorescent.
Fig. 9.11 (a) Intraand subretinal hemorrhage overlying a PED (upper left). Early during fluorescein angiography the PED (upper right) showed generalized decreased fluorescence with two areas of increased fluorescence, one contiguous with the retinal hemorrhage and a second area inferiorly. This patient was seen emergently because of a 3-day history of visual acuity change. The two lines correspond to sections examined with the EDI OCT. (Middle left) Later in the fluorescein angiogram, there was a generalized increase in fluorescence within the PED. (Middle right) Early during the indocyanine green (ICG) angiographic sequence, there were two areas of increased fluorescence
that corresponded to what was seen in the fluorescein angiogram. Since the pigmentation in the RPE is thought not to represent a major impediment to the passage of near-infrared light used in ICG angiography, the hyperfluorescent areas were considered to represent actual neovascularization and not transmission defects through the RPE. (Bottom left) The areas of hyperfluorescence increased in size in the midphase of the ICG angiogram (arrowheads). In the late phase of the ICG angiogram (bottom right), a larger underlying area of hyperfluorescence was visualized, consistent with a larger placoid area of choroidal neovascularization (arrows)
9 Fundus Imaging of AMD |
157 |
|
|
a
158 |
R.F. Spaide |
|
|
Fig. 9.11 (b) EDI OCT of a fibrovascular PED and its response to intravitreal ranibizumab treatment. The sections on the left correspond to the upper line in the early phase fluorescein angiogram and the sections on the right correspond to the second line. (Upper left) Prior to treatment the section through the “hotspot” on both the fluorescein and ICG angiograms shows a small collection of material posterior to the RPE within the PED. Note that the hyperreflective line corresponding to the RPE has variable thickness throughout the extent of the PED. (Upper right) A section taken inferiorly shows a more extensive accumulation of material along the back surface of the PED. There was an accumulation near the edge of the PED of similar material, but the extent of hyperfluorescence in the fluorescein and ICG angiograms cannot be attributed solely to this accumulation, implicating the material on the back surface of the PED as being fibrovascular in nature. (Middle left) One week after intravitreal ranibizumab injection, there was a partial collapse of the PED. Note the separation of the hyperreflective line (arrowhead) from the back surface of the PED. (Middle right) The correspondence in shape between the pretreatment and 1 week post treatment accumulation within the PED is more evident inferiorly. Note the separation and straightening of the sub-RPE material after the ranibizumab injection even though the PED is collapsing. This implies there was tensile traction within the detached material. (Bottom left and right) One month after injection, there was flattening of the PED over a hyperreflective material containing several subtle lamellae (From Spaide [32])
9.14Retinal Vascular Contribution to the Exudative Process
Although historic atlases of retinal disease have shown retinal vascular anastomosis with choroidal neovascularization, for many years, this condition was not mentioned. Over the last decade, interest in this condition increased and numerous theories developed about the anatomic structure of the anastomic connection. In a minority of patients, the retinal vessels appear to dive down and initiate vascular proliferation independent of the choroidal vasculature. These pro-
liferating vessels often occur in patients with focal hyperpigmentation. Other signs of retinal vascular proliferation are retinal vascular telangiectasis, dot hemorrhages within the retina, right angle veins and arteries, PEDs and microaneurysms. This condition was first described by Hartnett and coworkers as deep retinal vascular anomalous complexes (RVAC) [33]. It has been described by later authors as retinal angiomatous proliferation or RAP [34]. Still later Gass and colleagues [35] proposed that these patients have a chorioretinal anastomosis with occult choroidal neovascularization or ORCA. While the proposed
